10 results on '"Fernández, Laura"'
Search Results
2. Next‐generation sequencing reveals remarkable genetic stability in primary and corresponding recurrent intestinal‐type sinonasal adenocarcinoma.
- Author
-
Riobello, Cristina, Sánchez‐Fernández, Paula, Córdoba, María Camila Cubides, González‐Gutiérrez, Maripaz, Vivanco, Blanca, Cabal, Virginia N., Fernández, Laura Suárez, García‐Marín, Rocío, Codina‐Martínez, Helena, Lorenzo‐Guerra, Sara Lucila, López, Fernando, Hermsen, Mario A., and Llorente, José Luis
- Subjects
SECONDARY primary cancer ,NUCLEOTIDE sequencing ,SOMATIC mutation ,PARANASAL sinuses ,ADENOCARCINOMA - Abstract
Background: Recurrent intestinal‐type sinonasal adenocarcinoma (ITAC) can occur several years after primary treatment and with different histology. We aimed to clarify if such recurrences could be second primary tumors and to identify actionable mutations as targets for personalized treatment of recurrent ITAC. Methods: Twelve pairs of primary and recurrent ITAC were histologically examined and analyzed by next‐generation sequencing. Results: Histological differences between primary and recurrent tumor pairs were observed in five cases. Frequent mutations included TP53, APC, TSC2, ATM, EPHA2, BRCA2, LRP1B, KRAS, and KMT2B. There was 86% concordance of somatic mutations between the tumor pairs, while four cases carried additional mutations in the recurrence. Conclusions: We found all cases to be clonal recurrences and not second primary tumors. Moreover, tumor pairs showed a remarkable genomic stability, suggesting that personalized treatment of a recurrence may be based on actionable molecular genetic targets observed in the primary tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
- Author
-
Lorenzo-Guerra, Sara Lucila, Codina-Martínez, Helena, Suárez-Fernández, Laura, Cabal, Virginia N., García-Marín, Rocío, Riobello, Cristina, Vivanco, Blanca, Blanco-Lorenzo, Verónica, Sánchez-Fernández, Paula, López, Fernando, Llorente, Jóse Luis, and Hermsen, Mario A.
- Subjects
SOMATIC mutation ,PARANASAL sinuses ,CYCLIN-dependent kinase inhibitors ,ANIMAL models in research ,NEUROENDOCRINE cells - Abstract
Sinonasal teratocarcinosarcoma (TCS) is a rare tumor that displays a variable histology with admixtures of epithelial, mesenchymal, neuroendocrine and germ cell elements. Facing a very poor prognosis, patients with TCS are in need of new options for treatment. Recently identified recurrent mutations in SMARCA4 may serve as target for modern therapies with EZH1/2 and CDK4/6 inhibitors. Here, we present the first in vitro cell line TCS627, established from a previously untreated primary TCS originating in the ethmoid sinus with invasion into the brain. The cultured cells expressed immunohistochemical markers, indicating differentiation of epithelial, neuroepithelial, sarcomatous and teratomatous components. Whole-exome sequencing revealed 99 somatic mutations including SMARCA4, ARID2, TET2, CDKN2A, WNT7A, NOTCH3 and STAG2, all present both in the primary tumor and in the cell line. Focusing on mutated SMARCA4 as the therapeutic target, growth inhibition assays showed a strong response to the CDK4/6 inhibitor palbociclib, but much less to the EZH1/2 inhibitor valemetostat. In conclusion, cell line TCS627 carries both histologic and genetic features characteristic of TCS and is a valuable model for both basic research and preclinical testing of new therapeutic options for treatment of TCS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma.
- Author
-
Codina-Martínez, Helena, Lorenzo-Guerra, Sara Lucila, Cabal, Virginia N., García-Marín, Rocío, Suárez-Fernández, Laura, Vivanco, Blanca, Sánchez-Fernández, Paula, López, Fernando, Llorente, José Luis, and Hermsen, Mario A.
- Subjects
CELLULAR signal transduction ,PARANASAL sinuses ,DRUG target ,MTOR protein ,CELL communication - Abstract
Despite advances in surgery and radiotherapy, the overall prognosis of sinonasal intestinal-type adenocarcinoma (ITAC) is poor, and new treatment options are needed. Recent studies have indicated alterations in cellular signaling pathways that may serve as targets for modern inhibitors. Our aim was to evaluate the frequency of mTOR and ERK pathway upregulation in a retrospective series of 139 ITAC and to test the efficacy and mechanism of action of candidate targeted inhibitors in cell line ITAC-3. An immunohistochemical analysis on p-AKT, p-mTOR, p-S6, p-4E-BP1, and p-ERK indicated, respectively, a 68% and 57% mTOR and ERK pathway activation. In vitro studies using low doses of mTOR inhibitor everolimus and ERK inhibitor selumetinib showed significant growth inhibition as monotherapy and especially as combined therapy. This effect was accompanied by the downregulation of mTOR and ERK protein expression. Our data open a new and promising possibility for personalized treatment of ITAC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors.
- Author
-
Villanueva-Fernández, Eva, Hermsen, Mario A., Suárez-Fernández, Laura, Vivanco, Blanca, Franchi, Alessandro, García-Marín, Rocío, Cabal, Virginia N., Codina-Martínez, Helena, Lorenzo-Guerra, Sara Lucila, Llorente, José L., and López, Fernando
- Subjects
PARANASAL sinuses ,BIOMARKERS ,IMMUNE checkpoint inhibitors ,IMMUNOTHERAPY ,PROGRAMMED death-ligand 1 - Abstract
The sinonasal cavities harbor a wide variety of rare cancer types. Histopathological classification can be challenging, especially for poorly differentiated tumors. Despite advances in surgery and radio-chemotherapy, the 5-year survival rate is still very low. Thus, there is an unmet clinical need for new therapeutic options. We retrospectively evaluated poorly differentiated tumors of 9 different histological subtypes from 69 patients who had received conventional treatments for the presence of CD8+ tumor-infiltrating lymphocytes (TILs), as well as the expression of PD-L1 and microsatellite instability (MSI) markers MLH1, MSH2, MSH6 and PMS2, as biomarkers for immunotherapy. CD8+ TILs were present in 23/69 (33%) cases, PD-L1 expression was observed in 23/69 (33%), and markers for MSI positivity in 5/69 (7%) cases. CD8+ TILs correlated with PD-L1 positivity, while both were mutually exclusive with MSI markers. None of the biomarkers were associated with clinical features as age, gender or tumor stage. Cases with CD8+ TILs and PD-L1 positivity showed a tendency toward worse disease-specific survival. Immune checkpoint inhibitors are emerging as new options for treatment of many tumor types. Our results indicate that also a substantial subset of patients with poorly differentiated sinonasal tumors may be a candidate to be treated with this promising new therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
- Author
-
Riobello, Cristina, Casanueva Muruais, Rodrigo, Suárez‐Fernández, Laura, García‐Marín, Rocío, Cabal, Virginia N., Blanco‐Lorenzo, Verónica, Franchi, Alessandro, Laco, Jan, López, Fernando, Llorente, José Luis, and Hermsen, Mario A.
- Subjects
MELANOMA ,PARANASAL sinuses ,CANCER relapse ,IMMUNE checkpoint inhibitors ,NUCLEOTIDE sequencing ,BRAF genes - Abstract
Mucosal malignant melanoma (MMM) is a rare and aggressive tumor. Despite effective local therapies, tumor recurrence and metastasis remain frequent. The genetics of MMM remain incompletely understood. This study is aimed to identify actionable genetic alterations by next‐generation sequencing. Fifteen MMM samples were analyzed by next‐generation and Sanger sequencing. Gene copy number alterations were analyzed by MLPA. Mutation status was correlated with pERK, pAKT, and Ki‐67 expression and follow‐up data. Inactivating mutations and intragenic deletions in neurofibromatosis type‐1 (NF1) were identified in 3 and 2 cases, respectively, (in total 5/15, 33%) and activating mutations in NRAS and KRAS (3/15, 20%) cases. Other mutated genes included CDKN2A, APC, ATM, MITF, FGFR1, and FGFR2. BRAF and KIT mutations were not observed. Cases with NF1 alterations tended to have worse overall survival. The mutational status was not associated with pERK, pAKT, or Ki‐67 immunostaining. MMM carries frequent gene mutations activating the MAPK pathway, similar to cutaneous melanoma. In contrast, NF1 is the most frequently affected gene. Intragenic NF1 deletions have not been described before and may go undetected by sequencing studies. This finding is clinically relevant as NF1‐mutated melanomas have worse survival and could benefit from therapy with immune checkpoint and MEK inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Aberrant Signaling Pathways in Sinonasal Intestinal-Type Adenocarcinoma.
- Author
-
Riobello, Cristina, Sánchez-Fernández, Paula, Cabal, Virginia N., García-Marín, Rocío, Suárez-Fernández, Laura, Vivanco, Blanca, Blanco-Lorenzo, Verónica, Álvarez Marcos, César, López, Fernando, Llorente, José Luis, and Hermsen, Mario A.
- Subjects
ADENOCARCINOMA ,GENETIC mutation ,SEQUENCE analysis ,ONCOGENES ,CELLULAR signal transduction ,DESCRIPTIVE statistics ,NASAL tumors ,DNA damage - Abstract
Simple Summary: The majority of patients with sinonasal intestinal-type adenocarcinoma are wood and leather workers. However, the genetic changes that lead to these tumors are not well known. We analyzed 50 tumors for mutations in a set of 120 genes that may be involved in causing this cancer type. We found that 72% of cases carried mutations in genes that are active in Wnt, DNA damage response, MAPK or PI3K signaling pathways. Pathway activation was not related to mutations of genes in these pathways, except for nuclear β-catenin expression to Wnt pathway mutation. No specific gene mutation, mutated pathway, nor pathway activity level was associated with histological subtype, clinical data or survival. Finally, none of the identified mutated genes occurred in such frequency as to be considered a characteristic genetic feature of sinonasal intestinal-type adenocarcinoma. Sinonasal intestinal-type adenocarcinoma (ITAC) is strongly related to occupational exposure to wood and leather dust, however, little is known on the genetic alterations involved in tumor development and progression. The aim of this study was to identify tumorigenic signaling pathways affected by gene mutations and their relation to clinical features. We applied whole exome sequencing of 120 cancer-related genes in 50 ITACs and analyzed the signaling activity of four specific pathways frequently affected by mutations. Genes involved in DNA damage response showed somatic mutations in 30% of cases, including four tumors that also harbored germline mutations. Genes in Wnt, MAPK and PI3K pathways harbored mutations in 20%, 20% and 24% of cases, respectively. Mutations and copy number gains in receptor tyrosine kinases possibly affecting MAPK and PI3K pathways occurred in 44% of cases. Expression of key pathway proteins showed no correlation to mutations in these pathways, except for nuclear β-catenin and APC/CTNNB1 mutation. No specific gene mutation, mutated pathway, nor pathway activity level showed correlation to clinical data or survival. In addition, a similar mutational profile was observed among histological subtypes. The wide spectrum of gene mutations suggests that ITAC is a genetically heterogeneous without specific characterizing gene mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Prognostic and Therapeutic Implications of Immune Classification by CD8 + Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma.
- Author
-
García-Marín, Rocío, Reda, Sara, Riobello, Cristina, Cabal, Virginia N., Suárez-Fernández, Laura, Vivanco, Blanca, Álvarez-Marcos, César, López, Fernando, Llorente, José L., and Hermsen, Mario A.
- Subjects
SQUAMOUS cell carcinoma ,PROGRAMMED death-ligand 1 ,SURVIVAL rate ,IMMUNE checkpoint inhibitors ,PARANASAL sinuses ,NECK ,TUMOR-infiltrating immune cells - Abstract
Sinonasal squamous cell carcinoma (SNSCC) is an aggressive tumor predominantly arising in the maxillary sinus and nasal cavities. Advances in imaging, surgical and radiotherapeutic techniques have reduced complications and morbidity; however, the prognosis generally remains poor, with an overall 5-year survival rate of 30–50%. As immunotherapy may be a new therapeutic option, we analyzed CD8
+ tumor-infiltrating lymphocytes (TILs) and the tumor microenvironment immune type (TMIT, combining CD8+ TILs and PD-L1) in a series of 57 SNSCCs. Using immunohistochemistry, tissue samples of 57 SNSCCs were analyzed for expression of CD8 on TILs and of PD-L1 on tumor cells. The results were correlated to the clinical and survival data. In total, 88% (50/57) of the tumors had intratumoral CD8+ TILs; 19% (11/57)—CD8high (>10%); and 39/57 (68%)—CD8low (1–10%). PD-L1 positivity (>5%) was observed in 46% (26/57) of the SNSCCs and significantly co-occurred with CD8+ TILs (p = 0.000). Using univariate analysis, high intratumoral CD8+ TILs and TMIT I (CD8high /PD-L1pos ) correlated with a worse survival rate. These results indicate that SNSCCs are immunogenic tumors, similar to head and neck squamous cell carcinomas. Nineteen percent of the cases were both CD8high and PD-L1pos and this subgroup may benefit from therapy with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma.
- Author
-
García-Marín, Rocío, Reda, Sara, Riobello, Cristina, Cabal, Virginia N., Suárez-Fernández, Laura, Vivanco, Blanca, López, Fernando, Llorente, José L., and Hermsen, Mario A.
- Subjects
IMMUNE checkpoint inhibitors ,TUMORS ,LYMPHOCYTES ,CANCER ,IMMUNOTHERAPY - Abstract
Background. Intestinal-type adenocarcinoma (ITAC) is a rare tumour occurring in the ethmoid sinus. Recent years have brought advances in endoscopic surgery and precision radiotherapy; however, five-year overall survival has not improved and remains at 35–80%, depending on tumour stage and histology. Therefore, there is a need for new therapeutic options. Methods. We evaluated CD8
+ tumour-infiltrating lymphocytes (TILs) and tumour microenvironment immune type (TMIT, combining CD8+ TILs and PD-L1) as predictive biomarkers for immunotherapy in a series of 133 ITAC. All results were correlated to clinical and follow-up data. Results. The presence of intratumoural CD8+ TILs was low in 57% of cases and high in 8% of cases. Tumoural PD-L1 positivity was observed in 26% of cases. CD8+ TILs and TMIT correlated with the histological subtype of ITAC and with better overall survival. The presence of stromal PD-L1-positive macrophages was related to intratumoural CD8+ TILs. PD-L1 expression on tumour cells or macrophages did not show prognostic value. Conclusions. TMIT classification did not have additional prognostic value over CD8+ TILs alone. The modest percentage of CD8high /PD-L1pos cases indicates that ITAC is a lowly immunogenic tumour type. Nevertheless, a proportion of ITAC, especially the papillary and colonic subtypes, could benefit from therapy with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Translational genomics of sinonasal cancers.
- Author
-
Hermsen, Mario A., Riobello, Cristina, García-Marín, Rocío, Cabal, Virginia N., Suárez-Fernández, Laura, López, Fernando, and Llorente, José L.
- Subjects
- *
CANCER , *GENOMICS , *GENETIC testing , *CANCER treatment , *CAUSES of death - Abstract
The sinonasal cavities harbor a wide variety of histologically distinct cancers, the majority very aggressive with 5-year survival rates between 30–60% and local recurrence as the main cause of death. This is a complex anatomic area, close to structures such the eyes and the brain, which is of special relevance for surgery and postoperative radiotherapy. The low incidence of these rare tumors hampers accumulation of experience with diagnosis and clinical managment as well as knowledge on recurrent genetic aberrations or testing of new treatment strategies. However, recent years have seen a growing number of publications on genetic aberrations providing data that can aid or fine-tune classification and provide molecular targets for treatment with specific inhibitors. In addition, new sinonasal cancer models are created that enable preclinical testing of candidate inhibitor drugs. With more and more novel targeted therapies being developed, options for personalized treatment of sinonasal cancer patients are now opening up. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.